• Pfizer (NYSE:PFE) reported Q3 revenue of $16.58B vs. $15.87B expected, and adjusted EPS of $0.87 vs. $0.73 expected.
  • The company raised its full-year outlook, citing strong growth in launched and acquired products.
  • Despite the beat, questions remain about the sustainability of growth as COVID-19 revenue continues to normalize.

A Strong Quarter Amid Transition

Pfizer ($PFE) delivered third-quarter results that surpassed Wall Street expectations, with revenue of $16.58 billion and adjusted earnings per share of $0.87. Analysts had anticipated $15.87 billion in revenue and $0.73 in adjusted EPS. The company also reported net income of $3.24 billion. Shares rose in pre-market trading following the release.

The beat was driven by a 32% year-over-year operational increase in revenue from launched and acquired products, a key metric Pfizer has highlighted as it seeks to offset declining COVID-19-related sales. The company now forecasts full-year revenue of $62 billion to $64 billion and adjusted EPS of $2.95 to $3.05, up from its previous guidance of $60.5 billion to $62.5 billion and $2.80 to $3.00, respectively. The midpoint increases are $1.5 billion in revenue and $0.10 in EPS.

CEO Albert Bourla attributed the performance to the company's diversified portfolio. "Our strategy to replace pandemic-era revenue with new medicines is yielding results," he said in a statement. "We remain focused on delivering innovative therapies while managing costs to drive sustainable growth."

Beyond the Headlines

While the headline numbers are impressive, the underlying performance presents a more nuanced picture. The $16.58 billion in revenue is roughly flat compared to the $16.65 billion reported in the same quarter last year, and adjusted EPS of $0.87 matched the year-ago figure. Net income declined from $3.54 billion. The growth in launched and acquired products—which include newer medicines like Padcev and Lorbrena—is offsetting sharp declines in COVID-19 products. In the second quarter, Paxlovid revenue plunged 95% operationally, and Comirnaty fell 34%.

Investors are also watching for the impact of patent expirations. Eliquis, a key revenue driver, faces generic competition in some international markets. The company has been investing heavily in oncology and recently acquired Metsera (NASDAQ:MTSR) for up to $10 billion to bolster its obesity pipeline. However, those programs are still in development and not yet contributing to revenue.

Analysts at several firms noted that the beat was largely due to cost controls and lower-than-expected spending, rather than a significant top-line acceleration. "The guidance raise is encouraging, but the company still faces a steep cliff with COVID revenue and upcoming patent losses," wrote one healthcare analyst who requested anonymity. "The market will want to see consistent double-digit growth from the new products before fully buying into the recovery story."

Looking Ahead

Pfizer's restructuring efforts are also in focus. The company announced an additional $2.5 billion in anticipated savings through 2029, with associated implementation costs of about $6 billion. CFO Dave Denton departed in August, and Cecile Guegan is serving as interim CFO while the company searches for a permanent successor.

Regulatory developments could provide further tailwinds. Pfizer recently received FDA approvals for new indications of Tukysa and Talzenna plus Xtandi in cancer, and positive Phase 3 results for Elrexfio in multiple myeloma. The company is also awaiting data from its obesity candidate, berobenatide, with Phase 3 trials planned for 2026.

Pfizer will host a conference call with analysts at 10 a.m. ET to discuss the results. A company spokesperson did not immediately respond to a request for comment on the specifics of the pipeline.

Update: This article was updated to clarify that the revenue comparison is based on reported figures and that the year-over-year change is approximate.